Microalbuminuria and cardiorenal risk: Old and new evidence in different populations [version 1; peer review: 2 approved]

Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.Sin financiaciónNo data JCR 20191.357 SJR (2019) Q1, 51/271 Biochemistry, Genetics and Molecular Biology (miscellaneous), 5/111 Pharmacology, Toxicology and Pharmaceutics (miscellaneous), 300/2754 Medicine (miscellaneous); Q2, 17/61 Immunology and Microbiology (miscellaneous)No data IDR 2019UE